Abstract
This study investigates a unique form of androgen resistance in a family presenting with a qualitative defect in androgen receptor (AR) function. Genomic analysis revealed two distinct alterations in the AR gene: a single nucleotide substitution (A2444G) in exon 5, converting tyrosine 761 to cysteine (Tyr761Cys), and a shortened glutamine (Gln) homopolymeric segment in exon 1, encoding 12 instead of the typical 20-22 residues. By engineering these mutations individually and in combination into AR cDNAs, researchers demonstrated that while the Tyr761Cys mutation causes rapid hormone dissociation, the shortened Gln segment acts as a critical amplifier. Significant thermolability and a striking reduction in transcriptional activity were observed only when both mutations were present. These findings provide a molecular explanation for the clinical responsiveness of these patients to high-dose androgen therapy.
Introduction
Androgen Insensitivity Syndrome (AIS) typically results from mutations that either abolish AR expression or prevent hormone binding. However, some clinical cases involve "qualitative" defects where receptors are present but dysfunctional. This paper examines a family with such a defect who notably responded to high-dose androgen therapy, suggesting a complex molecular basis for their resistance. The study aims to determine if the clinical phenotype results from a single mutation or the interplay of multiple genetic variations.
Methods
The researchers sequenced the AR gene from the proband and established four cDNA constructs to isolate the effects of the identified mutations:
- Normal (A): 20 Gln residues, Tyr761.
- Gln12 (B): 12 Gln residues, Tyr761.
- Cys761 (C): 20 Gln residues, Cys761.
- Patient Q787 (D): 12 Gln residues, Cys761 (Double Mutant).
These constructs were transfected into mammalian cell lines (CHO, COS, CV1) for functional assays. The team measured hormone binding affinity, dissociation rates, and thermolability (stability at different temperatures). Additionally, they used a reporter gene (MMTV-CAT) to assess the ability of each receptor variant to trigger gene expression.
Results
The study revealed that the shortened Gln repeat (Gln12) is not a silent polymorphism but a functional amplifier of the Tyr761Cys defect.
- Transcriptional Activity: In reporter assays, the Cys761 mutation alone reduced AR activity to 51% of normal. However, the double mutant (Gln12 + Cys761) plummeted to just 7% activity.
- Thermostability: Only the double mutant exhibited marked thermolability in broken cell assays, losing nearly all binding capacity after 1 hour at 37°C, whereas the single point mutation (Cys761) remained relatively stable.
- Ligand Dissociation: The Tyr761Cys mutation caused the receptor to release dihydrotestosterone (DHT) much faster than normal.
- Therapeutic Rescue: Increasing the concentration of the synthetic androgen mibolerone from 1 nM to 20 nM significantly boosted the transcriptional activity of the double mutant, mirroring the clinical success of high-dose therapy.
Discussion
The interaction between the N-terminal Gln repeat and the C-terminal hormone-binding domain suggests significant inter-domain communication. While the exact structural mechanism remains to be defined, this "double-hit" model highlights how common genetic variations can modulate the severity of pathogenic mutations. This provides a molecular explanation for why high-dose therapy works: flooding the system with high concentrations of androgen helps keep the "fast-release" mutant receptor occupied and active long enough to trigger necessary gene expression. Future research should explore if Gln repeat length variations influence other AR-related conditions or normal physiological differences in male development.
Reference: McPhaul, M. J., et al. (1991). Molecular basis of androgen resistance in a family with a qualitative abnormality of the androgen receptor and responsive to high-dose androgen therapy. J. Clin. Invest. 87:1413-1421.
Summary updated